No advantage seen with long-term oxygen therapy for 24 versus 15 hours/day
By
Haymarket Media
Sep 10, 2024
For chronic, severe hypoxemia at rest, the risk for hospitalization or death within one year was comparable for oxygen therapy of 24 or 15 hours/day.
Low-dose triple-pill protocol lowers BP in Black Africans with hypertension
By
Haymarket Media
Sep 10, 2024
The mean home systolic blood pressure was lower with the triple-pill protocol versus the standard-care protocol at month 6.
Review weighs treatments for genitourinary symptoms of menopause
By
Haymarket Media
Sep 10, 2024
Vaginal estrogen, vaginal DHEA, oral ospemifene and vaginal moisturizers may be beneficial for some genitourinary symptoms.
Caseload strain linked to patient survival during delta wave of COVID-19
By
Haymarket Media
Sep 10, 2024
One in five COVID-19 deaths were due to strain-attributable mortality; the findings were consistent across hospital types.
Insulin resistance linked to risk for more than 30 diseases
By
Haymarket Media
Sep 09, 2024
Twenty-six positive and five negative correlations were seen, as well as a link between insulin resistance and all-cause mortality in women.
Clinical practice guideline developed for treatment of H. pylori infection
By
Haymarket Media
Sep 09, 2024
Bismuth quadruple therapy for 14 days is the preferred regimen for treatment-naive patients when antibiotic susceptibility is unknown.
Outdoor nighttime light exposure linked to prevalence of Alzheimer’s disease
By
Haymarket Media
Sep 06, 2024
Nighttime light exposure was more strongly linked to AD prevalence than any other disease factor among those younger than 65 years.
Adjunctive IV argatroban, eptifibatide do not cut disability after stroke
By
Haymarket Media
Sep 06, 2024
The findings were seen among patients with acute ischemic stroke who were treated with intravenous thrombolysis within three hours after symptom onset.
Asthma inhalers tied to large greenhouse gas emissions production
By
Haymarket Media
Sep 04, 2024
Metered-dose inhalers were responsible for almost all inhaler-related emissions.
Time from drug approval to reimbursement longer in US than some European countries
By
Haymarket Media
Sep 03, 2024
France has highest reimbursement rate one month after approval, while U.S. and Germany had no drugs reimbursed at one month